By Bhavna KavetiAug 23 2022Reviewed by Susha Cheriyedath, M.Sc. Dolutegravir is an antiretroviral drug used to treat human immunodeficiency virus in adults and children . However, this drug possesses solubility issues. An article published in Scientific Reports presented the fabrication of DTG-loaded chitosan nanoparticles with improved solubility and bioavailability.
Figure 1. The comparative HPLC chromatograms of Dolutegravir developed using a mixture of water, acetonitrile and methanol in the ratio of 20:40:40 with 0.2% formic acid as the mobile phase. System suitability; Dolutegravir with internal standard; low-level; mid-level; high-level of DTG concentrations. © K, P.D., D, R.D., S, B., Narayanan, H.B.
Generally, drug-loaded nanoparticle’s oral administration increases the cellular uptake, enhancing the exposure of the drug to plasma. Moreover, limiting the exposure of the drug to the enzymatic and non-enzymatic degradation in the gastrointestinal tract can enhance its bioavailability. Furthermore, the oral administration of a drug can increase cellular uptake and enhance the exposure of the drug to plasma. Moreover, loading the drug in nanoparticles reduces the susceptibility of the drug to enzymatic and non-enzymatic degradation in the GI tract. Thus, the present aim of increasing the bioavailability of the DTG drug was achieved by loading the drug into chitosan nanoparticles.